121 related articles for article (PubMed ID: 20807000)
1. Resveratrol. Monograph.
Altern Med Rev; 2010 Jul; 15(2):152-8. PubMed ID: 20807000
[No Abstract] [Full Text] [Related]
2. Pterostilbene. Monograph.
Altern Med Rev; 2010 Jul; 15(2):159-63. PubMed ID: 20807001
[No Abstract] [Full Text] [Related]
3. Resveratrol: a relevant pharmacological approach for the treatment of metabolic syndrome?
Beaudeux JL; Nivet-Antoine V; Giral P
Curr Opin Clin Nutr Metab Care; 2010 Nov; 13(6):729-36. PubMed ID: 20823772
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of resveratrol: the in vivo evidence.
Baur JA; Sinclair DA
Nat Rev Drug Discov; 2006 Jun; 5(6):493-506. PubMed ID: 16732220
[TBL] [Abstract][Full Text] [Related]
5. Silybin-phosphatidylcholine complex. Monograph.
Altern Med Rev; 2009 Dec; 14(4):385-90. PubMed ID: 20030465
[No Abstract] [Full Text] [Related]
6. Quercetin. Monograph.
Kelly GS
Altern Med Rev; 2011 Jun; 16(2):172-94. PubMed ID: 21649459
[No Abstract] [Full Text] [Related]
7. Milk thistle (Silybum marianum): an ancient botanical medicine for modern times.
Ross SM
Holist Nurs Pract; 2008; 22(5):299-300. PubMed ID: 18758279
[No Abstract] [Full Text] [Related]
8. Does cannabis hold the key to treating cardiometabolic disease?
Szmitko PE; Verma S
Nat Clin Pract Cardiovasc Med; 2006 Mar; 3(3):116-7. PubMed ID: 16505839
[No Abstract] [Full Text] [Related]
9. Resveratrol inhibits dimethylnitrosamine-induced hepatic fibrosis in rats.
Lee ES; Shin MO; Yoon S; Moon JO
Arch Pharm Res; 2010 Jun; 33(6):925-32. PubMed ID: 20607498
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of cardiovascular protection by resveratrol.
Hao HD; He LR
J Med Food; 2004; 7(3):290-8. PubMed ID: 15383221
[TBL] [Abstract][Full Text] [Related]
11. Targeting resveratrol to mitochondria for cardiovascular diseases.
Fan E; Zhang K
Recent Pat Cardiovasc Drug Discov; 2010 Jun; 5(2):97-102. PubMed ID: 20353381
[TBL] [Abstract][Full Text] [Related]
12. New progression in the study of protective properties of resveratrol in anticardiovascular disease.
Dong HH; Ren HL
Bratisl Lek Listy; 2004; 105(5-6):225-9. PubMed ID: 15535114
[TBL] [Abstract][Full Text] [Related]
13. Antioxidants in hypertension and cardiovascular disease.
Schiffrin EL
Mol Interv; 2010 Dec; 10(6):354-62. PubMed ID: 21263161
[TBL] [Abstract][Full Text] [Related]
14. Regulation of redox signalling and autophagy during cardiovascular diseases-role of resveratrol.
Fu DG
Eur Rev Med Pharmacol Sci; 2015 Apr; 19(8):1530-6. PubMed ID: 25967730
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol: biologic and therapeutic implications.
Sadruddin S; Arora R
J Cardiometab Syndr; 2009; 4(2):102-6. PubMed ID: 19614797
[TBL] [Abstract][Full Text] [Related]
16. Anti-atherogenic effects of resveratrol.
Ramprasath VR; Jones PJ
Eur J Clin Nutr; 2010 Jul; 64(7):660-8. PubMed ID: 20485301
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol and chemoprevention.
Goswami SK; Das DK
Cancer Lett; 2009 Oct; 284(1):1-6. PubMed ID: 19261378
[TBL] [Abstract][Full Text] [Related]
18. [Progress in cardiovascular protective effects of resveratrol].
Chen LN; Zang WJ; Tang YH
Sheng Li Ke Xue Jin Zhan; 2003 Jul; 34(3):272-4. PubMed ID: 14628481
[No Abstract] [Full Text] [Related]
19. Therapeutic applications of compounds in the Magnolia family.
Lee YJ; Lee YM; Lee CK; Jung JK; Han SB; Hong JT
Pharmacol Ther; 2011 May; 130(2):157-76. PubMed ID: 21277893
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases.
Knutson MD; Leeuwenburgh C
Nutr Rev; 2008 Oct; 66(10):591-6. PubMed ID: 18826454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
